Compare PCT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | IMCR |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | PCT | IMCR |
|---|---|---|
| Price | $9.33 | $38.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.67 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 4.5M | 317.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,660,000.00 | ★ $379,590,000.00 |
| Revenue This Year | N/A | $30.11 |
| Revenue Next Year | $770.11 | $8.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $5.40 | $23.15 |
| 52 Week High | $17.37 | $40.53 |
| Indicator | PCT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 61.19 |
| Support Level | $8.16 | $35.81 |
| Resistance Level | $8.85 | $40.53 |
| Average True Range (ATR) | 0.58 | 1.68 |
| MACD | 0.20 | -0.04 |
| Stochastic Oscillator | 95.55 | 79.67 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.